Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.

Locatelli F, Merli P, Rutella S.

J Leukoc Biol. 2013 Dec;94(6):1141-57. doi: 10.1189/jlb.0613343. Epub 2013 Oct 4. Review.

PMID:
24096380
[PubMed - indexed for MEDLINE]
2.

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.

Norell H, Moretta A, Silva-Santos B, Moretta L.

J Leukoc Biol. 2013 Dec;94(6):1123-39. doi: 10.1189/jlb.0613312. Epub 2013 Oct 9. Review.

PMID:
24108703
[PubMed - indexed for MEDLINE]
3.

Natural killer cells in the treatment of high-risk acute leukaemia.

Locatelli F, Moretta F, Brescia L, Merli P.

Semin Immunol. 2014 Apr;26(2):173-9. doi: 10.1016/j.smim.2014.02.004. Epub 2014 Mar 5.

PMID:
24613727
[PubMed - in process]
4.

Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.

Rezvani AR, Storb RF.

J Autoimmun. 2008 May;30(3):172-9. doi: 10.1016/j.jaut.2007.12.002. Epub 2008 Jan 31. Review.

PMID:
18242060
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Innate immunity against hematological malignancies.

Ruggeri L, Capanni M, Tosti A, Urbani E, Posati S, Aversa F, Martelli MF, Velardi A.

Cytotherapy. 2002;4(4):343-6. Review.

PMID:
12396834
[PubMed - indexed for MEDLINE]
7.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.

Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28.

PMID:
18573173
[PubMed - indexed for MEDLINE]
8.

Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.

Sinkovics JG.

Acta Microbiol Immunol Hung. 2010 Dec;57(4):253-347. doi: 10.1556/AMicr.57.2010.4.2. Review.

PMID:
21183421
[PubMed - indexed for MEDLINE]
9.
10.

Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation.

Locatelli F, Vinti L, Palumbo G, Rossi F, Bertaina A, Mastronuzzi A, Bernardo ME, Rutella S, Dellabona P, Giorgiani G, Moretta A, Moretta L.

Best Pract Res Clin Haematol. 2011 Sep;24(3):339-49. doi: 10.1016/j.beha.2011.04.004. Epub 2011 Jul 7. Review.

PMID:
21925087
[PubMed - indexed for MEDLINE]
11.

Cell therapy: achievements and perspectives.

Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A, Rondelli D, Zanon P, Tura S.

Haematologica. 1999 Dec;84(12):1110-49. Review.

PMID:
10586214
[PubMed - indexed for MEDLINE]
Free Article
12.

[Role of NK cells in allogeneic hematopoietic stem cell transplantation--review].

Li XH, Gao CJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Aug;14(4):845-8. Review. Chinese.

PMID:
16928336
[PubMed - indexed for MEDLINE]
13.

Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Björkström NK, Söderdahl G, Cederlund K, Kimby E, Aschan J, Ringdén O, Ljunggren HG, Dilber MS.

Immunotherapy. 2009 Sep;1(5):753-64. doi: 10.2217/imt.09.47.

PMID:
20636021
[PubMed - indexed for MEDLINE]
14.

Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.

Marcenaro E, Carlomagno S, Pesce S, Della Chiesa M, Moretta A, Sivori S.

J Leukoc Biol. 2011 Oct;90(4):661-7. doi: 10.1189/jlb.0311137. Epub 2011 Jul 26. Review.

PMID:
21791599
[PubMed - indexed for MEDLINE]
Free Article
15.

Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.

Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A.

Blood. 2011 Jan 20;117(3):764-71. doi: 10.1182/blood-2010-08-264085. Epub 2010 Oct 1. Review.

PMID:
20889923
[PubMed - indexed for MEDLINE]
Free Article
16.

Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.

Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kühne T, Favre G, Gratwohl A.

Leukemia. 2004 Nov;18(11):1835-8.

PMID:
15457184
[PubMed - indexed for MEDLINE]
17.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
[PubMed - indexed for MEDLINE]
18.

[Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].

Yu JP, Cao S, Xin N, An XM, Qi J, Ren XB.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):1013-8. Chinese.

PMID:
17956681
[PubMed - indexed for MEDLINE]
19.
20.

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A.

Science. 2002 Mar 15;295(5562):2097-100.

PMID:
11896281
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk